JPWO2019191119A5 - - Google Patents

Claims (30)

A method for making acetylated polysaccharides:
a) With the process of providing polysaccharides;
b) A step of purifying the polysaccharide to a purity of 1 to 90% by mass;
c) With the process of providing an acetylating agent;
d) With the process of providing the catalyst;
e) A step of mixing the acetylating agent and the catalyst with a polysaccharide to produce an acetylated polysaccharide, wherein this acetylation exceeds the acetylation of the polysaccharide in step a);
f) A method comprising the step of purifying the acetylated polysaccharide. The method according to claim 1, wherein the polysaccharide is a powder formulation. The method of claim 1, wherein the polysaccharide comprises glucomannan, glucogalactomannan, galactomannan, mannan and an acetylated form thereof. The method of claim 1, wherein the polysaccharide comprises a hydroxyl group and the hydroxyl group can be replaced with an acetyl group. The method of claim 1, wherein the polysaccharide comprises a mannose moiety. The method of claim 5, wherein the mannose moiety comprises a hydroxyl group and the hydroxyl group can be acetylated. The method of claim 6, wherein the acetylated polysaccharide comprises an acetyl group at the 2-, 3- and / or 6-positions of the mannose portion of the mannose moiety. The method of claim 1, wherein the acetylating agent is acetic anhydride (CH ₃ CO) ₂ O, acetyl chloride, and acetic acid. The method of claim 1, wherein the catalyst is pyridine, sodium hydroxide, potassium hydroxide, sodium carbonate, or potassium carbonate and a solvent. The method according to claim 1, wherein the purification step of step b) is carried out by ethanol precipitation. The method according to claim 1, wherein the purification step of step f) is carried out by a dialysis method. Acetylated polysaccharide produced by the method according to any one of claims 1 to 11. 12. The acetylated polysaccharide according to claim 12, which comprises at least one, two, or three acetyl groups per mannose group. The acetylated polysaccharide according to claim 12, which comprises a mannose group. The acetylated polysaccharide according to claim 12, wherein the polysaccharide comprises glucomannan, glucogalactomannan, galactomannan, mannan and / or an acetylated form thereof. The acetylated polysaccharide according to claim 12, which has a molecular weight in the range of about 1 to about 70 kilodaltons. The acetylated polysaccharide according to claim 12, which has a molecular weight of about 18 kilodaltons or about 29 kilodaltons. A pharmaceutical preparation comprising an acetylated polysaccharide produced by the method according to any one of claims 1 to 11 ; and a pharmaceutically acceptable excipient. The pharmaceutical preparation according to claim 18, further comprising a non-toxic auxiliary substance such as a wetting agent, a pH buffering agent, and an absorption-enhancing preparation. The pharmaceutical preparation according to claim 19, which is a pill, a tablet, a gummy candy, a capsule, a medicated drop or a liquid. 28. The pharmaceutical formulation of claim 18, for use in a method of treating, ameliorating or preventing an inflammatory response in a subject. The pharmaceutical preparation according to claim 21, wherein the subject suffers from an immune abnormality. The immunodeficiencies include systemic lupus, rhinitis, hemolytic anemia, vasculitis, type I diabetes, Graves disease, rheumatoid arthritis, multiple sclerosis, good pasture syndrome, myopathy, severe complex immunodeficiency, and DiGeorge syndrome. , Hyperimmunoglobulin E syndrome, unclassifiable immunodeficiency, chronic granulomatosis, Wiskott-Aldrich syndrome, autoimmune lymphoproliferative syndrome, hyperimmunoglobulin syndrome, leukocyte adhesion deficiency, NF-κB essential modifier (NEMO) ) The pharmaceutical preparation according to claim 22 , which is a mutation, selective immunoglobulin A deficiency, X-chain agammaglobulinemia, X-chain lymphoproliferative disorder or ataxia-telangiectosis. The pharmaceutical formulation of claim 18, for use in a method of treating an immune disorder in a subject . The immunodeficiencies include systemic lupus, rhinitis, hemolytic anemia, vasculitis, type I diabetes, Graves disease, rheumatoid arthritis, multiple sclerosis, good pasture syndrome, myopathy, severe complex immunodeficiency, and DiGeorge syndrome. , Hyperimmunoglobulin E syndrome, unclassifiable immunodeficiency, chronic granulomatosis, Wiskott-Aldrich syndrome, autoimmune lymphoproliferative syndrome, hyperimmunoglobulin syndrome, leukocyte adhesion deficiency, NF-κB essential modifier (NEMO) ) The pharmaceutical preparation according to claim 24 , which is a mutation, selective immunoglobulin A deficiency, X-chain agammaglobulinemia, X-chain lymphoproliferative disorder or ataxia-telangiectosis. The pharmaceutical formulation according to claim 18, for use in a method of increasing the expression of anti-inflammatory IL-10 (interleukin 10) in a subject . The pharmaceutical preparation according to claim 18, for use in a method for enhancing the expression of anti-inflammatory cytokines in a subject . The pharmaceutical formulation of claim 18, for use in a method of treating a tumor in a subject . 28. The apparatus of claim 28 , wherein the subject suffers from cancer and the tumor is from lung cancer, skin cancer, liver cancer, brain cancer, kidney cancer, or uterine cancer . Formulation . The pharmaceutical preparation according to claim 18, for use in a method of treating a viral or bacterial infection in a subject .